Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.

Seattle is among several major U.S. cities that are slowly sinking. That’s according to researchers at Virginia Tech, who ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Shares in British meat producer Cranswick slumped about 9% on Monday after UK supermarkets suspended supplies from one of its ...

Britain's Virgin Media O2 said it was combining its enterprise unit with business-to-business telecoms provider Daisy Group ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

ABC News chief medical correspondent Dr. Tara Narula breaks down what to know about a new study that says Zepbound may be ...